Clearmind Medicine CMND 深 滬
等待開盤 03-26 09:30:00 美东时间
0.72
+0.052
+7.78%
華盛通- 最 高0.72
- 今 開0.71
- 成交量 4.28万股
- 最 低 0.67
- 昨 收 0.668
- 總市值 129.23万
- 52周最高 52.40
- 市盈率 靜 --
- 換手率 2.38%
- 52周最低 0.5949
- 委 比 -63.77%
- 總股本 179.48万
- 歷史最高 7320.00
- 量 比 0.19
- 振 幅 7.49%
- 歷史最低 0.5949
- 每 手 1
- 風險率 17.60%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Clearmind Medicine To Continue Treatment Of Patients In Third Group Of Its Current FDA-Approved Phase I/IIa Clinical Study Of CMND-100 To Treat Alcohol Use Disorder
Clearmind Medicine Inc. (Nasdaq: CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived
03-19 21:42
Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder
Clearmind Medicine Inc. announced positive progress in its Phase I/IIa clinical trial of CMND-100 for treating Alcohol Use Disorder (AUD). The third cohort at Yale University, Johns Hopkins University, and Tel Aviv Sourasky Medical Center is proceeding successfully with no serious adverse events reported. CMND-100, a non-hallucinogenic MEAI-based oral drug, shows promise as a breakthrough therapy for AUD. The Company’s CEO expressed satisfaction ...
03-19 12:45
Clearmind Medicine Announces Continuation Of Participant Enrollment For Third Cohort Of Ongoing FDA-Approved Phase I/IIa Clinical Trial Evaluating CMND-100 For AUD Treatment
Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived
03-11 21:11
Clearmind Medicine's Interim Review For FDA-Approved Phase I/IIa Clinical Study For CMND-100 Completed By Data And Safety Monitoring Board
Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, second generation, neuroplastogen-derived
03-04 20:36
Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval
Clearmind Medicine Inc. has announced positive safety results from the second cohort of its Phase I/IIa clinical trial for CMND-100, a non-hallucinogenic neuroplastogen, in treating Alcohol Use Disorder (AUD). The independent Data and Safety Monitoring Board (DSMB) has recommended continuing the trial following the encouraging additional top-line data, which demonstrated a favorable safety profile and good tolerability. This paves the way for the...
03-04 12:30
Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments
Clearmind Medicine's proprietary compound MEAI (5-methoxy-2-aminoindane) has been included in U.S. federal legislation for the first time. The bipartisan bill, H.R. 7091, aims to expand access to innovative therapies for veterans, including MEAI, psilocybin, MDMA, and others, to address conditions like alcohol use disorder and PTSD. Clearmind CEO Dr. Adi Zuloff-Shani applauds the legislation, highlighting MEAI's potential to improve veterans' hea...
02-03 13:00
Clearmind Medicine Completes Treatment For All Patients In Second Cohort Of Ongoing FDA-Approved Phase I/IIa Clinical Trial Evaluating CMND-100 For AUD Treatment
Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major
01-14 21:57
Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100
Clearmind Medicine Inc. announced the successful completion of treatment for the second cohort in its Phase I/IIa clinical trial of CMND-100 for Alcohol Use Disorder. The six-patient cohort, recruited from leading medical centers, completed the trial following positive results from the first cohort, which showed favorable safety and efficacy signals. The company expects to release top-line results from the second cohort in the coming months.
01-14 13:55
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) stock increased by 19.2% to $1...
01-09 20:05
Dr. Adi Zuloff-Shani, CEO Of Clearmind Medicine Says "Looking Ahead To 2026, Clearmind Remains Focused On Advancing Its Pipeline, Generating Additional Clinical Data, And Exploring Strategic Opportunities To Maximize Shareholder Value And Patient Impact"
Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, commented: "2025 has been a pivotal year for Clearmind as we transitioned into a clinical-stage company, executing on our multinational trial. These achievements
2025-12-24 22:16
